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Simultaneous inhibition of multiple molecular targets is an established strategy to improve the continuance of clinical
response to therapy. Here, we screened 49 molecules with dual nanomolar inhibitory activity against BRD4 and
PLK1, best classified as dual kinase-bromodomain inhibitors, in pediatric tumor cell lines for their antitumor activity.
We identified two candidate dual kinase-bromodomain inhibitors with strong and tumor-specific activity against
neuroblastoma, medulloblastoma, and rhabdomyosarcoma tumor cells. Dual PLK1 and BRD4 inhibitor treatment
suppressed proliferation and induced apoptosis in pediatric tumor cell lines at low nanomolar concentrations. This
was associated with reduced MYCN-driven gene expression as assessed by RNA sequencing. Treatment of patient-
derived xenografts with dual inhibitor UMB103 led to significant tumor regression. We demonstrate that concurrent
inhibition of two central regulators of MYC protein family of protooncogenes, BRD4, and PLK1, with single small
molecules has strong and specific antitumor effects in preclinical pediatric cancer models.
Translational Oncology (2020) 13, 221–232Introduction
Solid tumors are one of the major causes of cancer-related death in
children [1]. The MYC family of transcription factors, in particular
MYC and MYCN (MYC/N), are one of the most highly investigated
oncogenic drivers in high-risk pediatric solid tumors. Amplification of
MYC/N often occurs in neuroblastoma, medulloblastoma, and
rhabdomyosarcoma, which are among the most prevalent pediatric
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adverse prognosis and is used to clinically stratify patients suffering
from neuroblastoma and medulloblastoma [5,6]. In rhabdomyosar-
coma, MYC/N is often either genomically amplified or expressed at
high levels because of the activity of the PAX3-FOXO1 fusion
oncoprotein [7]. Similar as in neuroblastoma and medulloblastoma,
MYC/N amplification is associated with adverse prognosis in
rhabdomyosarcoma [7]. The means by which MYC/N contributes
to features of high-risk tumors are still largely unclear. MYC/N
overexpression has pleiotropic effects and can lead to dysregulation of
cell proliferation, differentiation, and cell cycle progression leading to
increased tumor growth, thus representing an attractive therapeutic
target [8].
Given its importance for cancer, the regulation of oncogene
expression through transcriptional and posttranscriptional modes is a
matter of extensive research([9]). Transcription of oncogenes appears
to require regulation by an increased number and size of enhancer
elements. Large enhancer regions, called super-enhancers, are
abundant nearby genes encoding for lineage-specific transcription
factor genes in normal cells and can be found near oncogenes such as
MYC/N and PAX3-FOXO1 in cancer cells [7,10]. Regulation of
oncogenes by super-enhancers can be achieved through enhancer
translocations or other, as of yet unknown mechanisms [11].
Bromodomain-containing protein 4 (BRD4) has emerged as an
important factor in super-enhancer recognition through its binding to
acetylated lysine K27 of histone 3 [12]. BRD4 is essential for
transcriptional regulation of super-enhancereassociated genes
[12,13]. When being regulated by large super enhancers, MYC,
MYCN, and PAX3-FOXO1 transcription can be potently repressed by
pharmacological inhibition of BRD4 [7,14,15]. Although pharma-
cological BRD4 inhibition shows promising effects against preclinical
models of pediatric solid tumors, single agent treatment is not
curative in most cases treated so far [14e19].
Simultaneous inhibition of multiple therapeutic targets is an
established strategy to improve the durability of clinical responses
to targeted therapy. We and others have recently described that
combined treatment with small molecule BRD4 and polo-like
kinase 1 (PLK1) inhibitors has synergistic antitumor effects in
medulloblastoma and acute lymphoid leukaemia [20,21]. PLK1 is
overexpressed in pediatric solid tumors and high expression is
associated with poor prognosis [22e24]. PLK1 positively regulates
the stability of many oncoproteins, including MYC and MYCN
and PAX3-FOXO1. PLK1 does so, by increasing ubiquitin ligase
SCFFbw7 degradation, thereby preventing SCFFbw7emediated
MYC degradation [25]. Additionally, PLK1-mediated phosphor-
ylation of FOXO1 at Serine 503 directly prevents PAX3-FOXO1
degradation [23]. Consequently, simultaneous inhibition of BRD4
and PLK1 can lead to strong repression of MYC and MYCN
mRNA and protein expression resulting in profound antitumor
efficacy [21].
In recent years, small molecule inhibitors with dual-targeting
activity have been described [26e28]. Intriguingly, some PLK1
kinase inhibitors can simultaneously inhibit BET protein bromodo-
mains [29e34]. Here, we extend previous evidence that combination
of BRD4 and PLK1 inhibitors has synergistic antitumor effects in
pediatric tumor models and provide evidence for the therapeutic
activity of recently developed dual-targeting BRD4 and PLK1
inhibitors in preclinical models of pediatric tumors.Materials and Methods
Reagents and Chemicals
Materials and reagents were obtained from Carl Roth GmbH &
Co.KG unless otherwise specified. MK-8628 and Volasertib (BI
6727) were purchased from Selleckchem (Munich, Germany),
GSK461364 was purchased from Cayman chemical (Michigan,
US), and dual BRD4/PLK1 inhibitors (UMB analogs 88-161) were
produced as previously described [30]. UMB103 corresponds to
compound 12 and UMB160 corresponds to compound 23 in our
previous report describing the synthesis of these compounds [30].
MK-8628, Volasertib, and UMB88-UMB161 were dissolved in
dimethyl sulfoxide (DMSO) at a concentration of 10 mM, and stored
at 20 C for in vitro experiments.
Cell Culture
All cell lines (RH4, RH30, RD, T174, TE381.1, HD-MB03,
DAOY, ONS76, UW228, IMR5, GI-ME-N, NBL-S, Kelly, LAN-1,
and CHP-212) were obtained at American Type Culture Collection
(ATCC, Virginia, US) if not otherwise specified. Rh41, Rh18, Rh36,
TE441, and Kym1 were kindly provided by Prof. Simone Fulda. Cell
lines were cultured under standard conditions in Roswell Park
Memorial Institute medium 1640 (RPMI1640) or Dulbecco's
Modified Eagle Medium (DMEM) supplemented with 10% Fetal
Calf Serum (FCS, SigmaeAldrich, Missouri, USA) and 1%
Penicillin/Streptomycin (Thermo Fisher Scientific). The identity of
all cell lines was verified by STR genotyping (Genetica DNA
Laboratories), and cells were periodically checked with Lonza
MycoAlert system.
Cell Viability, Proliferation and Cell Cycle
Cell lines were seeded onto 96-well, white, flat bottom plates at a
concentration of 500 cells per well and incubated for 24 hours to
permit cell surface adherence. For examination of cell viability, cells
were treated in triplicates. Final concentration of DMSO was kept
below 1%. After 72 hours of treatment, relative ATP abundance was
measured using CellTiter Glo® (Promega, Wisconsin, USA)
according to the manufacturer's protocol. GloMax®Multi Detection
System (Promega) was used to measure the luminescence signal.
Measurement of relative BrdU abundance was measured in cells
seeded in 96-well, transparent, flat bottom multiwell plates at
500 cells per well. After 24 hours, cells were treated and incubated for
96 hours. Cell fixation and staining was performed according to the
manufacturer's instructions (Cell Proliferation ELISA, BrdU, colori-
metric, Roche, Basel, Switzerland). For cell cycle analysis, cells were
seeded in 100 mm petri dishes at 5  105 - 106 cells per dish. After
24 hours, cells were treated and incubated for 72 hours. Dual EdU
and propidium iodide labeling were performed according to the
manufacturer's protocol (Click-It EdU Alexa Fluor 488 Imaging Kit
Thermo Fisher Scientific). Cells were analyzed using the BD
LSRFortessa flow cytometer (BD Biosciences, California, USA).
Western Immuno Blotting
Whole-cell protein lysate preparation was performed with RIPA
buffer (15 mM HEPES, 150 mM NaCl, 10 mM EGTA, 2% Triton
X-100) supplemented with protease and phosphatase inhibitors
(complete mini EDTA-free and PhosSTOP, Roche) as described
before [14,21,35]. Bicinchoninic acid assay (Santa Cruz
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according to the manufacturer's protocol. Laemmli buffer was mixed
with cell lysates, denatured for 5 min at 95 C and loaded in a 10%
polyacrylamide gel (Thermo Fisher Scientific). Lysates were separated
by electrophoresis at 120 V and transferred to a PVDF membrane.
Membranes were blocked in 5% nonfat dry milk in TBS-T and
incubated in primary antibody in 5% nonfat dry milk in TBS-T
overnight at 4 C. Antibodies and dilutions are listed in
Supplementary Table 1. Membranes were washed three times and
incubated with the secondary antibody. Proteins were visualized with
ImmunoCruz Western Blotting Luminol Reagent (Santa Cruz
Biotechnology) and the Fusion FX7 imaging system was used for
detection (Vilber Lourmat).
RNA Sequencing
A total of 105 cells were seeded in 6-well plates and treated in
triplicates. Cells were harvested 6 hours and 24 hours after
treatment for rhabdomyosarcoma and neuroblastoma cells, respec-
tively. Total RNA was isolated from cell pellets using the RNeasy
mini kit (QIAGEN, Hilden, Germany) according to the manu-
facturer's protocol. Library preparation and sequencing was
performed by DKFZ Genomics and Proteomics Core Facility
(Deutsches Krebsforschungszentrum, Heidelberg, Germany).
Libraries were sequenced on a HiSeq 2000 v4 instruments with
2  125 bp paired-end reads (Illumina). Libraries were mapped
with STAR (version 2.5.3a) to GRCh38 using the Gencode v27
annotation and the following parametersdsjdbOverhang
300dtwopassMode BasicdoutReadsUnmapped NonedchimSeg-
m e n t M i n 1 2dc h i m J u n c t i o n O v e r h a n g M i n
12da l i gnS JDBove rhangMin 10da l i gnMa t e sGapMax
200000da l ignIntronMax 200000dl imi tBAMsortRAM
31532137230. Gene abundance was estimated using featureCounts
(version v1.5.1) and the following parameters -F GTF -t exon -g
gene_id -C -M efraction -p -s 0 -O -B -Q 4 allowing for fractional
counting of multimapping and multioverlapping reads with both
mates aligned and not counting chimeric reads. Standard differential
expression analysis for genes with at least 15 reads in at least one
sample among the groups considered was conducted using the
edgeR Bioconductor package [36].
Treatment of Patient-Derived Xenografts
All experiments were conducted according to the institutional
animal protocols and the national laws and regulations. The
experiments were conducted as previously described in four
replicates [35]. In short, NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac
mice (Taconic) were used to perform all patient-derived xenograft
experiments. Two neuroblastomas from two independent patients
with MYCN-amplified neuroblastoma were serially transplanted in
mice at least three times prior to the experiments. Caliper
measurement was used to monitor tumor growth. Tumor volume
was calculated with the formula length x width 2/2. Mice were
sacrificed with cervical dislocation when tumor size exceeded
2000 mm3. Drugs were dissolved in DMSO/Tween/0.9%NaCl and
administered intraperitoneally at 20 mg/kg body weight per day.
Immunohistochemistry
Immunopathological analysis was provided by the iPATH.Ber-
lindImmunopathology for Experimental Models, core unit of the
CharitedUniversit€atsmedizin Berlin (Berlin, Germany). Forma-lin-fixed tissue samples were embedded in paraffin and 1e2 mm
thick sections were cut from paraffin blocks. Sections were dewaxed
and histochemically stained with H&E (hematoxylin&eosin) for
evaluation of histomorphology or subjected to a heat-induced
epitope retrieval step prior to incubation with anti-Ki67 (clone
16A8, BioLegend), anticleaved caspase 3 (clone 5A1E, Cell
Signaling). For detection of Ki67 and cleaved caspase3, sections
were incubated with secondary antibody (biotinylated rabbit antirat
and biotinylated donkey antirabbit, respectively; Dianova). Biotin
was detected by streptavidin coupled with alkaline phosphatase
(AP) and RED as chromogen (both Dako REAL™ Detection
System, Alkaline Phosphatase/RED, Rabbit/Mouse, Agilent Tech-
nologies). Nuclei were counterstained with hematoxylin (Merck
Millipore) and slides coverslipped with glycerol gelatine (Merck).
Whole slide scans were acquired by a Vectra® 3 imaging system
(PerkinElmer).
Statistical Analysis
All other data analysis was performed using Excel 2013 and
GraphPad Prism 7. Synergism was analyzed with the R package
synergyfinder [37] or the free-license software Compusyn [38]. For
synergism analysis, only results of > IC10 and < IC90 were used.
RNASeq was analyzed as described.
Results
Combination Treatment with BRD4 and PLK1 Inhibitors has
Synergistic Antitumor Effects in Pediatric Tumor Cells
Based on previous reports showing synergistic antitumor effects of
combined treatment with BRD4 and PLK1 inhibitors in medullo-
blastoma and leukaemia [20,21], we hypothesized that combining
MK-8628 (BRD4 inhibitor) with Volasertib (PLK1 inhibitor) or
GSK461364 (PLK1 inhibitor) could show synergistic effects against
MYCN-driven neuroblastoma and rhabdomyosarcoma cells. To test
this, we assessed the effect of single agent treatment on neuroblastoma
and rhabdomyosarcoma cell line viability. In all cell lines treated with
either inhibitor, we observed a significant decrease in the number of
viable cells with increasing inhibitor concentrations (Supplementary
Figure 1, Table 2). Varying degrees of sensitivity were observed for
both inhibitors as evidenced by a wide range of IC50 concentrations
(Supplementary Figure 1 A and B). While BRD4 inhibitor,
MK-8628, was more effective in cells with high MYC/N expression
compared with cells with low MYC/N expression, cells did not
respond differentially to PLK1 inhibition with regard to their MYC/
N expression levels. To assess the effect of combined Volasertib,
GSK461364, and MK-8628 treatment in 12 neuroblastoma and
rhabdomyosarcoma cell lines, we calculated combination indices (CI)
and compared them with published results in four medulloblastoma
cell lines (Figure 1A) [21]. Synergistic effects on cell viability were
observed in 11 out of 16 cell lines, as evidenced by CI values below 1
(Figure 1A). No significant difference in synergy was observed
between cells with high MYC/N expression compared with cells
expressing low levels of MYC/N (Figure 1B). An excess over Bliss
analysis confirmed synergistic effects of combined PLK1 and BRD4
inhibitor treatment (Figure 1C and D, Supplementary Figure 2A and
B). Thus, combination treatment with BRD4 and PLK1 inhibitors
has significant synergistic low nanomolar antitumor activity rhabdo-
myosarcoma, neuroblastoma and medulloblastoma cells, independent
of MYC/N expression levels.
Figure 1. Combination of BRD4 and PLK1 inhibition has synergistic antitumoral effects in pediatric tumor cell lines. A Combination indices (CI)
of 16 pediatric tumor cell lines treated with varying concentrations of Volasertib and MK-8628 as well as combination of both
agents for 72 h. B Comparison of combination indices in cell lines with high and low MYC and/or MYCN expression. C Heatmap of
synergy score and excess over Bliss analysis of combination treatment with MK-8628 and Volasertib in MYCN-amplified
neuroblastoma cell line IMR5 and rhabdomyosarcoma cell line RH30. DHeatmap of synergy score and excess over Bliss analysis of
combination treatment with MK-8628 and GSK461364 in MYCN-amplified neuroblastoma cell line IMR5 and rhabdomyosarcoma
cell line RH30.
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Increased Cell Death
Previous reports have suggested that combined BRD4 and PLK1
inhibition leads to greater cellular apoptosis and cell cycle arrest
[15,39]. To confirm the effect of combination treatment observed in
other tumor entities in our neuroblastoma and rhabdomyosarcoma cellline models, we measured cell cycle distribution of cell lines after
treatment with MK-8628 and Volasertib, alone or in combination
(Figure 2A). Consistent with previous reports, synergistic effects on cell
viability were accompanied by significantly increasing fractions of
apoptotic cells (sub G1 phase) and a concomitant decreases in S phase,
compared with single agent treatment (Figure 2B and C and
Figure 2. Simultaneous inhibition of BRD4 and PLK1 synergistically represses MYC/N and results in increased cell death. A
Fluorescence-activated cell sorting (FACS)-based measurement of IMR5 cell cycle distribution after treatment with DMSO
control, MK-8628 (150 nM), Volasertib (5 nM), or combination of both agents (150 nM MK-8628 þ 5 nM Volasertib) for 72 h. B
Fraction of cells in S-phase as measured in (A). C Fraction of cells in Sub G1 phase as measured in A (A). DWestern immunoblotting
of MYCN and cleaved caspase 3 after treatment of cells with DMSO control, MK-8628 (500 nM), Volasertib (10 nM), or combination
of both (500 nM MK-8628 þ 10 nM Volasertib) (Student's t-test: * ¼ P < 0.05, ** ¼ P < 0.01, *** ¼ P < 0.001, **** ¼ P < 0.0001).
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aneuploidy, which may be due to effects of PLK1 inhibition on DNA
damage response leading to mitotic failure, in line with previous reports
(Figure 2) [40]. The increased cell death observed after combination
treatment was accompanied by significantly greater reduction of
MYCN protein levels compared with single agent treatment, which was
accompanied by increased caspase 3 cleavage, confirming on-target
BRD4 and PLK1 inhibition and induction of cellular apoptosis
(Figure 2D). In summary, combined PLK1 and BRD4 inhibition
disrupts neuroblastoma and rhabdomyosarcoma cell cycling, which is
accompanied by repression of BRD4 and PLK1 targets.Screening of 49 Small Molecules with Dual Inhibitory Activity
Against BRD4 and PLK1 Leads to the Discovery of Molecules
with Favourable In Vitro AntiTumor Activity Profiles
Based on the observed synergy of BRD4 and PLK1 inhibitors along
with the recent discovery of dual kinase-bromodomain inhibitors [30],
we hypothesized that dual BRD4/PLK1 inhibitors might have potent
antitumor activity and allow us to simultaneously target two regulators of
MYC/N using a single molecule. We performed an in vitro screen with a
recently developed small molecule library of dual BRD4/PLK1
inhibitors, called UMB88-162 (Figure 3A and B) [30]. Four tumor
cell lines (two rhabdomyosarcoma, one neuroblastoma, one medullo-
blastoma cell line) as well as one nontransformed human fibroblast cell
line were treated with each molecule at fixed drug concentrations
(Supplementary Figure 4AeE). Cell viability was assessed after 72 hours
of drug treatment and therapeutic efficacy compared. A therapeutic
index was calculated by comparing the effect of molecules on tumor cell
lines to the effect on nontransformed cells (Figure 3C). Two moleculeswith high dual BRD4 and PLK1 inhibitory activity, UMB160 and
UMB103, showed strong tumor cell-specific effects on cell viability
while having a broad therapeutic window as evidenced by low activity
against nontransformed cells. All other molecules with high therapeutic
window did not have measurable inhibitory potential on BRD4 and
were therefore not selected for further testing. Dose response analysis
revealed inhibitory concentrations with 50% reduction of cell viability
(IC50) values ranging from 2.9 to 87.5 nM and 6.5e178.2 nM for
UMB160 and UMB103, respectively (Supplementary Figure 5A to E,
Table 3). No difference in sensitivity was observed between cells
expressing high levels of MYC/N compared with cells expressing low
levels. Notably, rhabdomyosarcoma cell lines were more sensitive to both
candidate drugs compared with neuroblastoma and medulloblastoma
cells (Figure 3D). Both candidate molecules, UMB160 and UMB103
showed low nanomolar antitumor activity in cell lines, suggesting that
dual BRD4/PLK1 inhibitors may have clinically relevant activity.Dual BRD4/PLK1 Inhibitor Treatment Leads to Cell Death
and Cell Cycle Arrest in Pediatric Tumor Cell Lines
Based on the results of our screen, we reasoned that UMB160 and
UMB103 may affect important BRD4-and PLK1-regulated cellular
functions. To test this, we measured changes in cell cycle distribution
by performing EdU pulse labeling followed by fluorescence-activated
cell sorting (FACS) measurement in cells treated with UMB160 and
UMB103 (Figure 4A). Consistent with increased cell death, the
fraction of cells in sub G1 phase increased after treatment with
UMB160 and UMB103 (Figure 4C). Previous reports have shown
that BRD4 inhibition leads to cell cycle arrest in G1 because of
BRD4's critical role in cell cycle regulation [15]. Consistently, we
Figure 3. A library of dual nanomolar BRD4 and PLK1 inhibitors show varying antitumoral effects against pediatric tumor cell lines. A
Schematic of the selection strategy for the screening of 49 dual PLK1/BRD4 inhibitors. B Inhibitory concentrations 50% (IC50) of
dual inhibitor library against BRD4 and PLK1 as previously measured in cell free assays [30]. C Therapeutic index compared with
relative therapeutic efficacy of dual inhibitor library as measured at 20 nM concentration in pediatric tumor cell lines compared with
nontransformed human fibroblasts (candidate molecules are indicated in red and blue). D Dose-response area under the curve
(AUC) of 18 different pediatric tumor cell lines treated with dual PLK1/BRD4 inhibitors UMB103 (left) and UMB160 (right).
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fraction of cells S phase after treatment with UMB160 and UMB103
(Figure 4B and Supplementary Figure 6C). Moreover, UMB160 and
UMB103 led to an increase in the fraction of cells in G2/M phase
(Supplementary Figure 6D and G), in line with the function of PLK1
in G2/M regulation [39]. Consistent with decreased cell viability,
both UMB160 and UMB103 treatment led to a significant increase
in apoptosis, as evidenced by increased caspase 3 cleavage measured
by western immunoblotting (Figure 4D, Supplementary Figure 7A).
Taken together, treatment with dual BRD4/PLK1 inhibitors led to
reduction in cell viability and cell proliferation and to increased cell
death. In line with their ability to inhibit BRD4 and PLK1, cell cycle
was disrupted as previously observed for combined treatment with
PLK1 and BRD4 inhibitors and in line with known functions of
BRD4 and PLK1 in cell cycle regulation [21].Treatment with Dual BRD4/PLK1 Inhibitors Leads to
Repression of BRD4 and PLK1 Activity
To confirm on-target activity of UMB160 and UMB103 we
performed western immunoblotting analysis of known PLK1 andBRD4 targets after short-term inhibitor treatment. Both, UMB103 and
UMB160 treatment led to a significant repression of MYC in
MYC-amplified cells (Figure 5A). In PAX3-FOXO1-driven rhabdomyo-
sarcoma cells, treatment significantly repressed MYCN and FOXO1
expression, phenocopying the effect of BRD4 inhibition (Figure 5B).
Furthermore, phospho-PLK1 as well as PLK1 target WEE1 were
repressed after treatment with UMB160 but not UMB103, phenocopy-
ing the effect of PLK1 inhibition (Figure 5A). BRD4 and PLK1 protein
levels did not change after treatment, consistent with the disruption of
their activity rather than their stability. To further characterize the
molecular activity of the dual inhibitors, we performed RNA sequencing
after incubation of neuroblastoma and rhabdomyosarcoma cell lines with
dual inhibitors. Consistent with their inhibitory activity against BRD4
and PLK1, UMB160 and UMB103 treatment led to similar changes in
gene expression as observed after single PLK1 and BRD4 inhibitor
treatment (Supplementary Figure 7). Unsupervised clustering of
differentially expressed genes revealed that expression changes induced
by UMB160 and UMB103 were more similar to those observed after
PLK1 inhibition, suggesting that the impact of PLK1 inhibition on gene
expression was stronger compared with effects of BRD4 inhibition
Figure 4. Treatment with dual BRD4/PLK1 inhibitors UMB103 and UMB160 leads to cell death and cell cycle arrest in pediatric tumor cell lines.
A FACS-based measurement of the cell cycle distribution of IMR5 cells after treatment with DMSO, UMB103 (10 nM) or UMB160
(10 nM) for 72 hours. B Fraction of cells in S-phase as measured in (A). C Fraction of cells in Sub G1 phase as measured in (A). D
Western immunoblotting of cleaved caspase 3 after incubation of cells with DMSO compared with UMB103 and UMB160 for
24 hours at 20 nM each (Student's t-test: * ¼ ns ¼ not significant, P < 0.05, ** ¼ P < 0.01, *** ¼ P < 0.001, **** ¼ P < 0.0001).
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disrupt BRD4-regulated transcriptorial programs we compared our
results with previously published gene sets of PAX3-FOXO1 andMYCN
target genes, respectively [7,41]. Treatment with dual inhibitors led to
significant repression of PAX3-FOXO1 targets in rhabdomyosarcoma
(Supplementary Figure 7D) and ofMYCN targets in rhabdomyosarcoma
cells in line with potent inhibition of BRD4 (Figure 5D, Supplementary
Figure 7F). In neuroblastoma cells the effect of dual BRD4/PLK1
inhibitors on MYCN-driven gene expression was less pronounced,
consistent with the increased effects of UMB103 and UMB160 on
rhabdomyosarcoma cell viability. In conclusion, the disruption of
transcriptional programs by dual BRD4/PLK1 inhibitors phenocopies
changes induced by single BRD4 and PLK1 inhibitors, suggesting that
dual BRD4/PLK1 inhibitors have the potential to disrupt transcriptional
programs that are crucial for the survival of pediatric tumors.
Dual PLK1/BRD4 Inhibitors Show Significant Anti-Tumor
Effects Against High-Risk Neuroblastoma Patient-Derived
Xenografts (PDXs)
Based on the promising in vitro anti-tumor activity of dual BRD4/
PLK1 inhibitors, we hypothesized that these molecules may show
clinically relevant therapeutic activity in vivo. We chose UMB103 for
further in vivo testing. Based on the assumption of equal drug
distribution in mice, the dose applied (20 mg/kg body weight) was
expected to lead to a peak plasma concentration equalling 104 times
(ca. 20 mM) the estimated IC50 calculated from in vitro experiments.
No significant reduction in mouse weight was observed after treatment
at these doses. This suggests that concentrations at which inhibitors
show strong in vitro anti-tumor effects could be achieved withoutreaching toxic doses (Figure 3C). To investigate the therapeutic
efficacy of UMB103 in vivo we treated two independent MYCN-am-
plified high-risk neuroblastoma patient-derived xenograft models
(PDX) with UMB103. Mice were only treated once the tumor sizes
reached 200 mm3 and were exponentially growing, closely mimicking
clinical relapse or therapy-refractory situations at which such drugs
would be administered. At 20 mg/kg/d, UMB103 treatment led to
significant reduction of tumor growth in one of the PDX models
(Figure 6A). The fraction of proliferating cells as measured by
immunohistological staining for Ki67 significantly decreased in tumors
responding to UMB103 treatment whereas apoptotic cells, as
measured by cleaved caspase 3 staining increased (Figure 6C).
UMB103 treatment was accompanied by increased caspase 3 cleavage,
suggesting that treatment showed strong cytostatic and significant
cytotoxic effects in vivo (Figure 6E). Together, treatment with
UMB103 significantly repressed proliferation and induced apoptosis
in vivo at non-toxic doses, which led to reduced tumor growth over
time. This suggests that dual PLK1/BRD4 inhibitors have the
potential to show clinically relevant therapeutic activity in patients
suffering from high-risk pediatric solid tumors.
Discussion
Bromodomain-containing protein 4 (BRD4) inhibitors have shown
promising preclinical activity in various tumor models [18,19].
However, as with most small molecule inhibitors, it is likely that
single-agent inhibitor treatment will not be curative in most patients.
In line with our previous reports in medulloblastoma [21], we here
demonstrate that combination of BRD4 and PLK1 inhibitors has
synergistic in vitro activity against preclinical models of
Figure 5. Treatment with dual nanomolar BRD4/PLK1 inhibitors leads to repression of BRD4 and PLK1 functions. AWestern immunoblotting
of BRD4 and PLK1 targets after incubation of HD-MB03 medulloblastoma cells with DMSO, MK-8628 (500 nM), Volasertib (5 nM),
or combination of both, UMB160 (10 nM) or UMB103 (10 nM) for 24 hours. Signal quantification is plotted below. B Western
immunoblotting of MYCN after treatment of IMR5 neuroblastoma cells with DMSO, MK-8628 (500 nM), Volasertib (5 nM), or
combination of both, GSK461364 (100 nM) or combination of GSK461364 and MK-8628, UMB160 (10 nM) or UMB103 (10 nM) for
24 hours. Signal quantification is plotted below. CWestern immunoblotting of MYCN in RH30 rhabdomyosarcoma cells treated for
24 hours with increasing concentrations of UMB160 or UMB103. D Unsupervised clustering of differentially expressed genes as
measured by RNA sequencing of MYCN-amplified neuroblastoma cell line IMR5 treated with MK-8628 (500 nM) and/or Volasertib
(10 nM) compared with UMB103 (100 nM) or UMB160 (100 nM) for 24 hours. E Gene set enrichment analysis (GSEA) plot for MYCN
target genes, as previously defined [41], in neuroblastoma cell line IMR5 and rhabdomyosarcoma cell line RH4 treated with dual
PLK1/BRD4 inhibitors.
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Figure 6. Dual nanomolar BRD4/PLK1 inhibitors show significant antitumor effects against patient-derived xenograft models
(PDXs) of high-risk MYCN-amplified neuroblastomas. A-B Tumor volumes of two independent neuroblastoma patient-derived
models treated with UMB103 at 20 mg/kg/d (N ¼ 4 mice per group, patient A ¼ MYCN-amplified 15 month of age at the time of
diagnosis, B ¼MYCN-amplified, 2 month of age at the time of diagnosis). C Photomicrographs of tumor sections from PDX shown
in (A) immunohistochemically stained for Hematoxylin and eosin (H&E, blue) and Ki67 (left, red) and cleaved caspase 3 (right, red).
D Quantification of Ki67 and cleaved caspase 3 expression as shown in (C). EWestern immunoblotting of cleaved caspase 3 in PDX
tumors shown in (A) treated with UMB103 compared with tumors treated with DMSO and compared with untreated IMR5 cells. F
Quantification of relative protein expression of cleaved caspase 3 (Student's t-test: ns¼ not significant, *¼ P < 0.05, **¼ P < 0.01,
*** ¼ P < 0.001, **** ¼ P < 0.0001).
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of this treatment strategy extends to other pediatric solid tumor
entities. Through a small molecule in vitro screen for agents with dual
BRD4/PLK1 inhibitory activity, we identify two candidate molecules
with promising preclinical anti-tumor activity in vitro and in vivo.
Consistent with on-target dual BRD4/PLK1 inhibition, treatment
with candidate molecules led to concomitant disruption of transcrip-
tional programs controlled by BRD4 and reduced PLK1 kinase
activity. We conclude that dual BRD4/PLK1 inhibition represents a
promising approach for the treatment of pediatric solid tumors
relying on BRD4 and PLK1 activity.
Cancer commonly acquires mutations during the course of
treatment that lead to treatment resistance. Targeting more thanone process in cancer cells can drastically reduce the probability of
treatment resistance [42]. This is supported by the fact that
combination of cytotoxic therapies has drastically improved the
survival rates in children in the past decades [43]. However, long term
side effects of chemotherapy as well as radiation therapy such as organ
damage, secondary malignancies, and fatigue constitute considerable
sequelae can cause considerable morbidity and mortality after
successful first-line treatment [43]. Such adverse side effects occur
less commonly when multiple modes of action are synergistically
targeted [44]. Additionally, reducing the number of active agents and
development of targeted therapies may reduce side effects and lead to
reduced usage of cytotoxic conventional chemo- and radiation
therapy. Though many highly selective targeted therapies have yet to
230 Small-Molecule Dual PLK1 and BRD4 Inhibitors Timme et al. Translational Oncology Vol. 13, No. 2, 2020achieve clinical results, it is widely accepted that synergistic targeted
treatment approaches will not only reduce the risk of treatment
resistance but have the potential to improve outcome by reducing
long term adverse effects.
One example for effective combination of targeted agents are
recently proposed combinations of BRD4 inhibitors with other
small molecules, which can synergistically increase anti-tumor
effects in preclinical models of various tumor entities [45e51].
While these results are promising, a selection of ideal drug
combinations for the treatment of pediatric tumors is hampered
by the fact that most studies on combination treatments have been
performed in tumor models that, on a molecular level, differ
significantly from pediatric tumors. Combined inhibition of BRD4
and PLK1 was recently reported to show synergistic antitumor
effects in preclinical models of medulloblastoma and acute myeloid
leukaemia [20,21]. Consistent with these reports, we observed
significant synergistic anti-tumor effects when combining MK-8628
with Volasertib or GSK461364 in preclinical models of three
pediatric tumor entities. These effects were accompanied with
significant repression of MYC and MYCN expression, reduced
PLK1 kinase activity as well as disruption of cell cycling as predicted
based on BRD4 and PLK1 functions. Thus, we and others clearly
demonstrate on-target synergistic anti-tumor effects of BRD4 and
PLK1 inhibitors.
Even though multi target therapies such as combination of BRD4
and PLK1 inhibitors have several excellent rationales, clinical
development of combination therapies remains difficult. Testing
therapeutic activity and safety is more arduous for combination
regimens, as single drugs need to be approved separately prior to
clinical testing of combination treatment. Additionally, pharmacoki-
netics of different molecules are difficult to predict leading to
difficulties in planning correct treatment schedules. Notably, complex
treatment regimens and multiple different drug administrations lead
to lower patient compliance [52]. Thus, novel approaches are clearly
needed to enable the rapid and efficient introduction of synergistic
therapeutic strategies into clinical settings.
One possibility to circumvent difficulties resulting from
combination treatments is the use of molecules that simultaneously
and specifically inhibit two or more cancer-relevant targets.
Molecules with multiple targets are often more effective against
advanced diseases; they have more predictable pharmacokinetic
profile compared with combination therapy, especially if adverse
effects are molecule-based. Additionally, using a single compound
guarantees that synergistic effects occur simultaneously regardless of
the pharmacokinetics of the drug [42]. Recent reports suggest that
some kinase inhibitors have the ability to bind to the bromodomain
of BRD4 and to inhibit kinase activity simultaneously [29]. We
recently created a library of small molecules with high affinity to
BRD4 as well as PLK1 by chemically modifying BI-2536 analogues
[30]. In our in vitro screen presented here, we find that a subset of
dual-targeting molecules can suppress the viability, proliferation and
cell cycling of pediatric tumor cell lines at low nanomolar
concentrations. This is in line with recent reports showing the
feasibility of simultaneously targeting bromodomains and Phos-
phoinositide 3-kinases (PI3K) in pancreatic and neuroblastoma cell
lines [34]. As treatment of pediatric tumor cells with dual BRD4/
PLK1 inhibitors is accompanied by inhibition of important BRD4
and PLK1 functions in gene expression regulation as well as
kinase-mediated cell signalling, we conclude that it is feasible toinhibit both BRD4 and PLK1 with a single molecule in cancer cells.
Furthermore, we observe a clear repression of tumor growth in one
patient derived high-risk neuroblastoma tumor model treated with
the dual BRD4/PLK1 inhibitor UMB103. Importantly, these
antitumor effects were not accompanied by significant overall
toxicity. This is in line with previous reports of low toxicity in
several dual inhibitors [42,52,53]. Even though tumor regression
was not complete and only one out of two PDX models responded
suggesting yet unknown determinants of treatment response, we
conclude that dual BRD4/PLK1 inhibition may have the potential
to generate a substantial response in pediatric patients suffering from
high-risk solid tumors.
In summary, we here present the unique approach of therapeu-
tically targeting two independent cancer-relevant proteins. Based on
a screen with a dual kinase-bromodomain small-molecule library, we
discovered chemical leads serving as a starting point for therapeutic
development. Dual BRD4/PLK1 inhibitors have the potential to
generate a measurable response in patients suffering from
neuroblastoma. This new insight should provide a translational
framework for clinical trial development of dual inhibitors for
pediatric patients. Apart from the potential clinical benefit for
patients suffering from high-risk solid tumors, introduction of
dual-targeting agents may avoid the pharmacological difficulties
associated with the administration of two different drugs, thereby
expediting clinical development and avoiding accumulation of
off-target side effects.
Authors' Contributions
NT investigation, data curation and writing original draft, YH
investigation, SL investigation, HOY investigation, HDG investiga-
tion and supervision, YB investigation and software, FK investigation,
software and supervision, ICMA investigation, AS investigation, VB
investigation, CD investigation, AK supervision, JR in vivo studies,
PH supervision, AL supervision, GS supervision, AE supervision,
JHS supervision, WZ supervision, AGH conceptualization, funding
acquisition, writing&editing, supervision. NT and AGH wrote the
manuscript with contribution from all authors.
Conflicts of Interest
The authors have no conflict of interest to declare.
Funding
A.G.H. is supported by the Deutsche Forschungsgemeinschaft
(DFG, German Research Foundation)d398299703, the Wilhelm
Sander Stiftung. A.G.H. and A.K. are participants in the BIH-Charite
C l i n i c a l S c i e n t i s t P r o g r am funded by th e Cha r -
itedUniversit€atsmedizin Berlin and the Berlin Institute of Health.
A.G.H. is supported by Berliner Krebsgesellschaft e.V. A.K. is
supported by the Else Kr€oner-Fresenius Stiftung. A.G.H. is
supported by TransOnc priority program of the German Cancer
Aid within grant “70112951” (ENABLE).
Acknowledgments
The authors are grateful to Alex Kentsis and Nicole Hübener for
critical discussions, and Kathy Astrahantseff for editorial advice. We
thank the patients and their parents for granting access to the tumor
specimen and clinical information that were analyzed in this study.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2019.09.013.
Translational Oncology Vol. 13, No. 2, 2020 Small-Molecule Dual PLK1 and BRD4 Inhibitors Timme et al. 231References
[1] Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M and Clavel J, et al
(2014). Childhood cancer survival in Europe 1999-2007: results of
EUROCARE-5–a population-based study. Lancet Oncol 15(1), 35e47.
[2] Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD and Jay V, et al
(2000). Molecular cytogenetic analysis of medulloblastomas and supratentor-
ial primitive neuroectodermal tumors by using conventional banding,
comparative genomic hybridization, and spectral karyotyping. J Neurosurg
93(3), 437e448.
[3] Barr FG, Duan F, Smith LM, Gustafson D, Pitts M and Hammond S, et al
(2009). Genomic and clinical analyses of 2p24 and 12q13-q14 amplification
in alveolar rhabdomyosarcoma: a report from the Children's Oncology
Group. Genes Chromosomes Cancer 48(8), 661e672.
[4] Schwab M (2004). MYCN in neuronal tumours. Cancer Lett 204(2),
179e187.
[5] Davidoff AM (2012). Neuroblastoma. Semin Pediatr Surg 21(1), 2e14.
[6] Miranda Kuzan-Fischer C, Juraschka K and Taylor MD (2018). Medullo-
blastoma in the molecular era. J Korean Neurosurg Soc 61(3), 292e301.
[7] Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J and Wachtel M, et al
(2017). PAX3-FOXO1 establishes myogenic super enhancers and confers
BET bromodomain vulnerability. Cancer Discov 7(8), 884e899.
[8] Gustafson WC and Weiss WA (2010). Myc proteins as therapeutic targets.
Oncogene 29(9), 1249e1259.
[9] Esteller M (2006). Epigenetics provides a new generation of oncogenes and
tumour-suppressor genes. Br J Canc 94(2), 179e183.
[10] Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V and Sigova AA, et al
(2013). Super-enhancers in the control of cell identity and disease. Cell
155(4), 934e947.
[11] Loven J, Hoke HA, Lin CY, Lau A, Orlando DA and Vakoc CR, et al
(2013). Selective inhibition of tumor oncogenes by disruption of super-
enhancers. Cell 153(2), 320e334.
[12] Wu SY and Chiang CM (2007). The double bromodomain-containing
chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 282(18),
13141e13145.
[13] Yang Z, He N and Zhou Q (2008). Brd4 recruits P-TEFb to chromosomes
at late mitosis to promote G1 gene expression and cell cycle progression. Mol
Cell Biol 28(3), 967e976.
[14] Henssen A, Althoff K, Odersky A, Beckers A, Koche R and Speleman F, et al
(2016). Targeting MYCN-driven transcription by BET-bromodomain
inhibition. Clin Cancer Res 22(10), 2470e2481.
[15] Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N and Beckers A,
et al (2013). BET bromodomain protein inhibition is a therapeutic option for
medulloblastoma. Oncotarget 4(11), 2080e2095.
[16] Noel JK, Iwata K, Ooike S, Sugahara K, Nakamura H and Daibata M
(2013). Development of the BET bromodomain inhibitor OTX015. In:
Proceedings of the AACR-NCI-EORTC International Conference: Mole-
cular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA, 12;
2013 (11 Supplement):Abstract number C244.
[17] Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E and Tarantelli C, et al
(2015). The BET bromodomain inhibitor OTX015 affects pathogenetic
pathways in preclinical B-cell tumor models and synergizes with targeted
drugs. Clin Cancer Res 21(7), 1628e1638.
[18] Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P and Bourdel F, et al
(2016). Phase I population pharmacokinetic assessment of the oral
bromodomain inhibitor OTX015 in patients with haematologic malignan-
cies. Clin Pharmacokinet 55(3), 397e405.
[19] Xu Y and Vakoc CR (2017). Targeting cancer cells with BET bromodomain
inhibitors. Cold Spring Harb Perspect Med 7(7).
[20] Tontsch-Grunt U, Rudolph D, Waizenegger I, Baum A, Gerlach D and
Engelhardt H, et al (2018). Synergistic activity of BET inhibitor BI 894999
with PLK inhibitor volasertib in AML in vitro and in vivo. Cancer Lett 421,
112e120.
[21] Han Y, Lindner S, Bei Y, Garcia HD, Timme N and Althoff K, et al (2019).
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib
in preclinical models of medulloblastoma. Cancer Lett 445(31), 24e33.
[22] Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V and Hero B,
et al (2011). Polo-like kinase 1 is a therapeutic target in high-risk
neuroblastoma. Clin Cancer Res 17(4), 731e741.[23] Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R,
Laubscher D and Gierisch ME, et al (2015). PLK1 phosphorylates PAX3-
FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyo-
sarcoma. Cancer Res 75(1), 98e110.
[24] Triscott J, Lee C, Foster C, Manoranjan B, Pambid MR and Berns R, et al
(2013). Personalizing the treatment of pediatric medulloblastoma: polo-like
kinase 1 as a molecular target in high-risk children. Cancer Res 73(22),
6734e6744.
[25] Xiao D, Yue M, Su H, Ren P, Jiang J and Li F, et al (2016). Polo-like kinase-
1 regulates myc stabilization and activates a feedforward circuit promoting
tumor cell survival. Mol Cell 64(3), 493e506.
[26] Watts E, Heidenreich D, Tucker E, Raab M, Strebhardt K and Chesler L,
et al (2019). Designing dual inhibitors of anaplastic lymphoma kinase
(ALK) and bromodomain-4 (BRD4) by tuning kinase selectivity. J Med Chem
62(5), 2618e2637.
[27] Sonawane V, Mohd Siddique MU, Jadav SS, Sinha BN, Jayaprakash V
and Chaudhuri B (2019). Cink4T, a quinazolinone-based dual inhibitor
of Cdk4 and tubulin polymerization, identified via ligand-based virtual
screening, for efficient anticancer therapy. Eur J Med Chem 165,
115e132.
[28] Cheng G, Wang Z, Yang J, Bao Y, Xu Q and Zhao L, et al (2019). Design,
synthesis and biological evaluation of novel indole derivatives as potential
HDAC/BRD4 dual inhibitors and anti-leukemia agents. Bioorg Chem 84,
410e417.
[29] Ciceri P, Muller S, O'Mahony A, Fedorov O, Filippakopoulos P and
Hunt JP, et al (2014). Dual kinase-bromodomain inhibitors for rationally
designed polypharmacology. Nat Chem Biol 10(4), 305e312.
[30] Liu S, Yosief HO, Dai L, Huang H, Dhawan G and Zhang X, et al (2018).
Structure-guided design and development of potent and selective dual
bromodomain 4 (BRD4)/Polo-like kinase 1 (PLK1) inhibitors. J Med Chem
61(17), 7785e7795.
[31] Mao F, Li J, Luo Q, Wang R, Kong Y and Carlock C, et al (2018).
Plk1 inhibition enhances the efficacy of BET epigenetic reader blockade
in castration-resistant prostate cancer. Mol Cancer Ther 17(7),
1554e1565.
[32] Zhu H, Mao JH, Wang Y, Gu DH, Pan XD and Shan Y, et al (2017). Dual
inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell
carcinoma cell growth. Oncotarget 8(58), 98471e98481.
[33] Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M and Tauro M, et al
(2017). Potent dual BET bromodomain-kinase inhibitors as value-added
multitargeted chemical probes and cancer therapeutics. Mol Cancer Ther
16(6), 1054e1067.
[34] Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA and Garlich JR, et al
(2017). Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of
MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A
114(7), E1072eE1080.
[35] Henssen AG, Reed C, Jiang E, Garcia HD, von Stebut J and MacArthur IC,
et al (2017). Therapeutic targeting of PGBD5-induced DNA repair
dependency in pediatric solid tumors. Sci Transl Med 9(414).
[36] Robinson MD and Smyth GK (2007). Moderated statistical tests for assessing
differences in tag abundance. Bioinformatics 23(21), 2881e2887.
[37] deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C and Cherba D,
et al (2018). Discordant inheritance of chromosomal and extrachromosomal
DNA elements contributes to dynamic disease evolution in glioblastoma. Nat
Genet 50(5), 708e717.
[38] Chou TC (2010). Drug combination studies and their synergy quantification
using the Chou-Talalay method. Cancer Res 70(2), 440e446.
[39] Liu X and Erikson RL (2003). Polo-like kinase (Plk)1 depletion induces
apoptosis in cancer cells. Proc Natl Acad Sci U S A 100(10), 5789e5794.
[40] Marder BA and Morgan WF (1993). Delayed chromosomal instability
induced by DNA damage. Mol Cell Biol 13(11), 6667e6677.
[41] Westermann F, Muth D, Benner A, Bauer T, Henrich KO and Oberthuer A,
et al (2008). Distinct transcriptional MYCN/c-MYC activities are associated
with spontaneous regression or malignant progression in neuroblastomas.
Genome Biol 9(10), R150.
[42] Reddy AS and Zhang S (2013). Polypharmacology: drug discovery for the
future. Expert Rev Clin Pharmacol 6(1), 41e47.
[43] Kizilocak H and Okcu F (2019). Late effects of therapy in childhood acute
lymphoblastic leukemia survivors. Turk J Haematol 36(1), 1e11.
232 Small-Molecule Dual PLK1 and BRD4 Inhibitors Timme et al. Translational Oncology Vol. 13, No. 2, 2020[44] Calhoun DA (2009). Use of single-pill combination therapy in the evolving
paradigm of hypertension management. Expert Opin Pharmacother 10(12),
1869e1874.
[45] Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S and Sanchez-
Rivera FJ, et al (2015). Combined inhibition of BET family proteins and
histone deacetylases as a potential epigenetics-based therapy for pancreatic
ductal adenocarcinoma. Nat Med 21(10), 1163e1171.
[46] Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F and Wang J,
et al (2016). BET and BRAF inhibitors act synergistically against BRAF-
mutant melanoma. Cancer Med 5(6), 1183e1193.
[47] Vazquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K and Erba E,
et al (2017). The bromodomain inhibitor OTX015 (MK-8628) exerts anti-
tumor activity in triple-negative breast cancer models as single agent and in
combination with everolimus. Oncotarget 8(5), 7598e7613.
[48] Yang L, Zhang Y, Shan W, Hu Z, Yuan J and Pi J, et al (2017). Repression of
BET activity sensitizes homologous recombination-proficient cancers to
PARP inhibition. Sci Transl Med 9(400).[49] Lam LT, Lin X, Faivre EJ, Yang Z, Huang X and Wilcox DM, et al (2017).
Vulnerability of small-cell lung cancer to apoptosis induced by the
combination of BET bromodomain proteins and BCL2 inhibitors. Mol
Cancer Ther 16(8), 1511e1520.
[50] Enssle JC, Boedicker C, Wanior M, Vogler M, Knapp S and Fulda S
(2018). Co-targeting of BET proteins and HDACs as a novel approach
to trigger apoptosis in rhabdomyosarcoma cells. Cancer Lett 428,
160e172.
[51] Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N and
Kossenkov AV, et al (2017). BET bromodomain inhibition synergizes
with PARP inhibitor in epithelial ovarian cancer. Cell Rep 21(12),
3398e3405.
[52] Peters JU (2013). Polypharmacology - foe or friend? J Med Chem 56(22),
8955e8971.
[53] Carlino L and Rastelli G (2016). Dual kinase-bromodomain inhibitors in
anticancer drug discovery: a structural and pharmacological perspective.
J Med Chem 59(20), 9305e9320.
